Cetuximab antibody | AbD19834_hIgG1
Human anti Cetuximab
Anti-cetuximab antibody is a recombinant, neutralizing anti-idiotypic antibody in fully human IgG1 format, suitable for bioanalytical method development for cetuximab and biosimilars. It can be used as detection antibody in ELISA and as a high affinity reference standard in an ADA bridging ELISA.
- Product Type
- Monoclonal Antibody
|Product Code||Applications||Datasheet||MSDS||Pack Size||List Price||Quantity|
Human anti Cetuximab, clone AbD19834_IgG1 is a fully human antibody and is particularly suited as a calibrator for immune response assays to measure the anti-drug antibody (ADA) levels in patient sera.
Cetuximab (brand name Erbitux®) is a chimeric monoclonal antibody drug (IgG1/kappa) approved for treatment of KRAS wild-type metastatic colorectal cancers and squamous cell carcinoma of the head and neck. This therapeutic antibody is directed against EGFR and inhibits tumor cell proliferation by blocking the interaction of epidermal growth factor (EGF) with its receptor.
View a summary of all anti cetuximab antibodies.
- Product Form
- Human IgG1 antibody selected from the HuCAL® phage display library and expressed in a human cell line. This product is supplied as a liquid.
- Purified IgG prepared by affinity chromatography on Protein A
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.01% Thiomersal
- The monovalent intrinsic affinity of HCA222 was measured as KD = 0.5 nM by real time, label free molecular interaction analysis on immobilized cetuximab.
- Approx. Protein Concentrations
- IgG concentration 0.5 mg/ml
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- 12 months from date of despatch
- Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.
Erbitux® is a registered trademark of ImClone LLC, a wholly-owned subsidiary of Eli Lilly and Company.
- Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
- For research purposes only
Applications of Cetuximab antibody
|Application Name||Verified||Min Dilution||Max Dilution|
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual
- This product is suitable for use in direct ELISA applications or as a bridging reagent in ADA assays.
Protocol: PK bridging ELISA to measure free drug
Protocol: ADA bridging ELISA
Useful Reagents Available
|Description||Product Code||Pack Size||Applications||List Price||Quantity|
|Hispec Assay Diluent||BUF049A||50 ml||E IY|
|LYNX Rapid HRP Antibody Conjugation Kit||LNK002P||3 Conjugations For 400µg Antibody||CJ|
Product Specific References
Gomez, D. et al. (2013) Cetuximab therapy in the treatment of metastatic colorectal cancer: the future frontier?
Int J Surg. 11 (7): 507-13.